Tadalafil Tablet, Film Coated
Product Images NDC 68788-4083

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 68788-4083). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 01)

Chemical structure diagram of tadalafil, showing the arrangement of its atoms and bonds in a two-dimensional format.*

FDA Label Image

Image (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 02)

This image consists of four line graphs depicting the difference in blood pressure between tadalafil and placebo over time in hours. The graphs show standing systolic BP, standing diastolic BP, supine systolic BP, and supine diastolic BP, with measurements extending up to 96 hours. Each graph illustrates mean blood pressure changes with error bars indicating variability.*

FDA Label Image

Image (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 03)

Two line graphs displaying blood pressure changes over 24 hours post-dose. The top graph shows standing systolic blood pressure (mmHg) over time with lines for tadalafil 20 mg combined with doxazosin 8 mg and placebo with doxazosin 8 mg. The bottom graph depicts supine systolic blood pressure (mmHg) changes over the same period comparing the same two treatments.*

FDA Label Image

Image (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 04)

Line chart depicting changes in systolic blood pressure (mmHg) over 12 hours after administration of tadalafil 20 mg or placebo, both combined with 8 mg daily doxazosin, measured at two time points (08:00 and 20:00). The graph shows multiple time-series lines comparing blood pressure effects of the drug versus placebo over time.*

FDA Label Image

Image (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 05)

A pharmacokinetic line graph depicting plasma tadalafil concentration (µg/L) over time (hours) for different dosing regimens: single 20-mg dose, single 5-mg dose, and once-daily 5-mg dose following 5 consecutive days. The graph shows concentration declining after dosing with error bars indicating variability.*

FDA Label Image

Image (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 06)

A line graph depicting the change from baseline in IPSS total score over a 12-week treatment duration. The graph compares tadalafil 5 mg and placebo, showing a greater decrease in IPSS score for tadalafil over time. The x-axis represents treatment duration in weeks, and the y-axis represents the change from baseline in IPSS score. Statistical significance is indicated at p<0.01.*

FDA Label Image

Image (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 07)

A line graph comparing change from baseline in IPSS total score over 12 weeks between Tadalafil 5 mg and placebo. The x-axis represents treatment duration in weeks, and the y-axis shows change in score. Tadalafil shows a larger decrease than placebo, with a noted statistical significance at certain points (p < 0.01).*

FDA Label Image

Image (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 08)

A line graph depicting least-squares mean change from baseline over 26 weeks of therapy comparing tadalafil/finasteride and placebo/finasteride. The vertical axis shows the change measures, while the horizontal axis indicates weeks of therapy at 0, 4, 12, and 26 weeks. Data points show a greater reduction for tadalafil/finasteride compared to placebo/finasteride over time, with statistical significance markers noted.*

FDA Label Image

Image (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 09)

A line graph depicting the change from baseline in IPSS total score over a 12-week treatment duration. The graph compares Tadalafil 5 mg and placebo groups, showing score changes at 0, 2, 4, 8, and 12 weeks. Tadalafil shows a greater reduction in score than placebo over time.*

FDA Label Image

Unichem Logo (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 10)

FDA Label Image

Image (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 11)

FDA Label Image

Tadalafil Tablets 20mg (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 17)

Label for Tadalafil Tablets 20 mg film-coated tablets by Preferred Pharmaceuticals Inc. The label states the product is generic for Cialis and manufactured by Unichem Laboratories Ltd. It includes storage instructions, dosing directions in English and Spanish, and warnings about prescription use. The tablet is described as oval, yellow, and imprinted with U/289.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.